Edding Genor climbs on approval of clinical trial of cancer drug in China

Edding Genor group

03/07/2026 04:41

** Shares of Edding Genor Group Holdings 6998.HK climb 6.9% to HK$1.87, on track for the biggest one-day pct gain since March 30
** Stock touches the highest point since June 23 in the second rising session 
** Biopharmaceutical products developer says Investigational New Drug (IND) application for Phase Ib/II clinical trial of the company's GB268 for treatment of locally advanced unresectable or metastatic breast cancer has been approved by China's National Medical Products Administration 
** Company says it expects to initiate multiple combination therapy clinical studies in additional advanced solid tumor indications 
** YTD, stock down 39.3%, Hang Seng Biotech Index .HSBIO down 3.2%
     
     

(Reporting by Donny Kwok)
((donny.kwok@thomsonreuters.com))